So who loses? That's the insight. There is a loser. The loser is the supplier of EPO. There is one company that's almost synonymous with EPO, and that's Amgen (AMGN). In truth, though, Amgen is no longer as reliant on EPO as it once was. But still, checking its latest 10-Q we learn that 22.3% of its revenues come from EPO (Aranesp, Epogen). While not as relevant as it once was, it's still nearly 1/4th of Amgen's revenue base.
Possible suitors for Rockwell would be DaVita (DVA), Fresenius (FMS), Takeda or AMGEN (AMGN), all key players in the kidney dialysis market.
Following the clinical date released on SFP, I expect Calcitriol to increase sales and profit margins considerably while strengthening the existing business. Rockwell's strong data also supports Soluble Ferric Pyrophosphate with the possibility of setting a new standard of care for hemodialysis patients.
SFP is a "game changer" and will significantly raise the bar in the IV iron therapy market for dialysis patients. I still anticipate that we will see an $11 - $12 price on the stock once investors discover the potential that this company brings to the dialysis market and upgrades follow.